Page 1383 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 75 Hodgkin Lymphoma 1229

REFERENCES with BEACOPP in advanced-stage Hodgkin lymphoma patients
with a interim-PET positive after two ABVD courses. Br J Haematol
1. Green MR, Monti S, Rodig SJ, et al: Integrative analysis reveals selective 152(5):551–560, 2011.
9p24.1 amplification, increased PD-1 ligand expression, and further 15b. Avigdor A, Bulvik S, Levi I, et al: Two cycles of escalated BEACOPP
induction via JAK2 in nodular sclerosing Hodgkin lymphoma and followed by four cycles of ABVD utilizing early-interim PET/CT scan is
primary mediastinal large B-cell lymphoma. Blood 116(17):3268–3277, an effective regimen for advanced high-risk Hodgkin’s lymphoma. Ann
2010. Oncol 21(1):126–132, 2010.
2. Cheson BD, Fisher RI, Barrington SF, et al: Recommendations for 16. Batlevi CL, Younes A: Novel therapy for Hodgkin lymphoma. Hematol-
initial evaluation, staging, and response assessment of Hodgkin and ogy Am Soc Hematol Educ Program 2013:394–399, 2013.
non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 17. Josting A, Rueffer U, Franklin J, et al: Prognostic factors and treatment
32(27):3059–3068, 2014. outcome in primary progressive Hodgkin lymphoma: a report from the
3. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin’s German Hodgkin Lymphoma Study Group. Blood 96(4):1280–1286,
disease. International Prognostic Factors Project on Advanced Hodgkin’s 2000.
Disease. N Engl J Med 339(21):1506–1514, 1998. 18. Josting A, Franklin J, May M, et al: New prognostic score based on treat-
4. Raemaekers JMM, André MPE, Federico M, et al: Omitting radiother- ment outcome of patients with relapsed Hodgkin’s lymphoma registered
apy in early positron emission tomography-negative stage I/II Hodgkin in the database of the German Hodgkin’s lymphoma study group. J Clin
lymphoma is associated with an increased risk of early relapse: Clinical Oncol 20(1):221–230, 2002.
results of the preplanned interim analysis of the randomized EORTC/ 19. Linch DC, Winfield D, Goldstone AH, et al: Dose intensification
LYSA/FIL H10 trial. J Clin Oncol 32(12):1188–1194, 2014. with autologous bone-marrow transplantation in relapsed and resis-
5. Radford J, Barrington S, Counsell N, et al: Involved field radiotherapy tant Hodgkin’s disease: results of a BNLI randomised trial. Lancet
versus no further treatment in patients with clinical stages IA and IIA 341(8852):1051–1054, 1993.
Hodgkin lymphoma and a ‘negative’ PET scan after 3 cycles ABVD: 20. Schmitz N, Pfistner B, Sextro M, et al: Aggressive conventional che-
Results of the UK NCRI RAPID Trial. Blood 120:547, 2012. motherapy compared with high-dose chemotherapy with autologous
6. Longo DL, Young RC, Wesley M, et al: Twenty years of MOPP therapy haemopoietic stem-cell transplantation for relapsed chemosensitive
for Hodgkin’s disease. J Clin Oncol 4(9):1295–1306, 1986. Hodgkin’s disease: a randomised trial. Lancet 359(9323):2065–2071,
6a. Bonadonna G, Zucali R, Monfardini S, et al: Combination chemo- 2002.
therapy of Hodgkin’s disease with adriamycin, blemycin, vinblastine, 21. Josting A, Müller H, Borchmann P, et al: Dose intensity of chemo-
and imidazole carboxamide versus MOPP. Cancer 1975:252–259, 1975. therapy in patients with relapsed Hodgkin’s lymphoma. J Clin Oncol
7. Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced 28(34):5074–5080, 2010.
Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with 22. Moskowitz AJ, Yahalom J, Kewalramani T, et al: Pretransplantation
ABVD. N Engl J Med 327(21):1478–1484, 1992. functional imaging predicts outcome following autologous stem cell
8. Viviani S, Bonadonna G, Santoro A, et al: Alternating versus hybrid transplantation for relapsed and refractory Hodgkin lymphoma. Blood
MOPP and ABVD combinations in advanced Hodgkin’s disease: ten- 116(23):4934–4937, 2010.
year results. J Clin Oncol 14(5):1421–1430, 1996. 23. Moskowitz CH, Matasar MJ, Zelenetz AD, et al: Normalization of
9. Connors JM, Klimo P, Adams G, et al: Treatment of advanced Hodgkin’s pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant,
disease with chemotherapy–comparison of MOPP/ABV hybrid regimen chemotherapy programs improves event-free survival in patients with
with alternating courses of MOPP and ABVD: a report from the Hodgkin lymphoma. Blood 119(7):1665–1670, 2012.
National Cancer Institute of Canada clinical trials group. J Clin Oncol 24. Younes A, Bartlett NL, Leonard JP, et al: Brentuximab vedotin (SGN-35)
15(4):1638–1645, 1997. for relapsed CD30-positive lymphomas. N Engl J Med 363(19):1812–
10. Duggan DB, Petroni GR, Johnson JL, et al: Randomized comparison of 1821, 2010.
ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s 25. Younes A, Gopal AK, Smith SE, et al: Results of a pivotal phase II study
disease: report of an intergroup trial. J Clin Oncol 21(4):607–614, 2003. of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s
11. Diehl V, Sieber M, Rüffer U, et al: BEACOPP: an intensified chemo- lymphoma. J Clin Oncol 30(18):2183–2189, 2012.
therapy regimen in advanced Hodgkin’s disease. The German Hodgkin’s 26. Ansell SM, Lesokhin AM, Borrello I, et al: PD-1 blockade with niv-
Lymphoma Study Group. Ann Oncol 8(2):143–148, 1997. olumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med
12. Engert A, Diehl V, Franklin J, et al: Escalated-dose BEACOPP in the 372(4):311–319, 2015.
treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years 27. Younes A, Sureda A, Ben-Yehuda D, et al: Panobinostat in patients with
of follow-up of the GHSG HD9 study. J Clin Oncol 27(27):4548–4554, relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell trans-
2009. plantation: results of a phase II study. J Clin Oncol 30(18):2197–2203,
13. Carde PP, Karrasch M, Fortpied C, et al: ABVD (8 cycles) versus 2012.
BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk 28. Younes A, Oki Y, Bociek RG, et al: Mocetinostat for relapsed classical
Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup Hodgkin’s lymphoma: an open-label, single-arm, phase 2 trial. Lancet
randomized phase III clinical trial. J Clin Oncol 30(Suppl 15s), 2012. Oncol 12(13):1222–1228, 2011.
Abstract 8002. 29. Johnston PB, Pinter–Brown L, Rogerio J, et al: Everolimus for Relapsed/
13a. Mournier N, Brice P, Bologna S, et al: Lymphoma Study Association Refractory Classical Hodgkin Lymphoma: Multicenter, Open-Label,
(LYSA): ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 base- Single-Arm, Phase 2 Study. ASH Annual Meeting Abstracts 120(21):2740,
line): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) 2012.
of the LYSA H34 randomized trial. Ann Oncol 25(8):1622–1628, 2014. 29a. Oki Y, Buglio D, Fanale M, et al: Phase I study of panobinostat plus
14. Viviani S, Zinzani PL, Rambaldi A, et al: ABVD versus BEACOPP for everolimus in patients with relapsed or refractory lymphoma. Clin Cancer
Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med Res 29(24):6882–6890, 2013.
365(3):203–212, 2011. 30. Fehniger TA, Larson S, Trinkaus K, et al: A phase 2 multicenter study
18
15. Gallamini A, Hutchings M, Rigacci L, et al: Early interim 2-[ F]fluoro- of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.
2-deoxy-D-glucose positron emission tomography is prognostically Blood 118(19):5119–5125, 2011.
superior to international prognostic score in advanced-stage Hodgkin’s 30a. Engert A, Ballova V, Haverkamp H, et al: Hodgkin’s lymphoma in
lymphoma: a report from a joint Italian-Danish study. J Clin Oncol elderly patients: a comprehensive retrospective analysis from the German
25(24):3746–3752, 2007. Hodgkin’s Study Group. J Clin Oncol 23(22):5052–5060, 2005.
15a. Gallamini A, Patti C, Viviani S, et al: Gruppo Italiano Terapie
Innovative nei Linfomi (GITIL): Early chemotherapy intensification